Table 1.

Comparison of eligibility criteria for the DAPA-CKD trial and other contemporary Phase 3 trials recruiting participants with CKD and T2D (from clinicaltrials.gov)

Parameter	DAPA-CKD	EMPA-KIDNEY	FLOW
Study drug	Dapagliflozin	Empagliflozin	Semaglutide
Comparator	Placebo	Placebo	Placebo
Recruitment	4000	6000	3160
Non-diabetic CKD included	Yes	Yes	No
T1D	Excluded	Included	Excluded
Background ACEi/ARB	Unless not tolerated	Unless not tolerated or not indicated	Unless not tolerated or contraindicated
Age (years)	≥18	≥18	≥18 (Japan ≥20)
eGFR range	≥25–≤75 mL/min/1.73 m²	≥20–≤90 mL/min/1.73 m²	≥25–≤75 mL/min/1.73 m²
UACR range	≥200 mg/g to ≤5000 mg/g	≥200 mg/g if eGFR ≥45 to <90 mL/min/1.73 m²	≥300–≤5000 mg/g, ≥100 mg/g if eGFR ≤50 mL/min/1.73 m²